What InventisBio does

InventisBio (益方生物科技（上海）股份有限公司) is a Shanghai-headquartered, publicly listed (SSE STAR Market: 688382) clinical- and early-commercial-stage biotechnology company developing self-discovered small-molecule therapeutics for oncology, autoimmune diseases, and metabolic disorders. Founded in 2013 by Dr. Yaolin Wang and a team of ex-Merck and Schering-Plough scientists, the company operates a structure-based drug design platform that has produced a pipeline of internally developed kinase inhibitors, oral SERDs, and synthetic-lethality candidates. Its most advanced asset, Garsorasib (D-1553 / Anfangning), is a highly selective oral KRAS G12C inhibitor that received NMPA approval in November 2024 for KRAS G12C-mutant advanced NSCLC and is being expanded into pancreatic and colorectal cancer indications; additional clinical-stage assets include D-2570 (TYK2 JH2 inhibitor, Phase III for psoriasis), D-0502/taragarestrant (oral SERD, Phase III for HR+/HER2- breast cancer), and D-0120/darbinurad (URAT1 inhibitor for hyperuricemia, Phase IIb completed).

The company makes money primarily through licensing and milestone payments from commercial partners, supplemented by nascent product sales. Garsorasib is commercialized in mainland China under an exclusive license with Chia Tai Tianqing (CTTQ), which handles development, registration, production, and commercialization — InventisBio receives milestones and royalties. The earlier EGFR-T790M inhibitor D-0316 was out-licensed to Betta Pharmaceuticals for Greater China rights in exchange for 230 million RMB in upfront and milestone payments plus royalties. The company has not disclosed product pricing, and ex-China commercial rights for Garsorasib remain unpartnered. Headquartered in Shanghai's Zhangjiang Pharma Valley with additional R&D operations in Beijing and a US clinical/regulatory presence in New Jersey, InventisBio is led by its founder-Chairman-CEO and a senior team averaging over 20 years of big-pharma R&D experience, including leadership roles on Merck's Keytruda program.

Name

InventisBio

Legal name

益方生物科技（上海）股份有限公司

Website

https://inventisbio.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

InventisBio is a Shanghai-listed, clinical- and early-commercial-stage Chinese biotech developing self-discovered small-molecule drugs for oncology, autoimmune, and metabolic diseases, with two approved products and two Phase III assets.

Ownership category

akta.pro rank

Product category

Targeted Small-Molecule Oncology and Immunology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Small-molecule drug discovery
• Targeted oncology therapeutics
• Kinase inhibitor development
• Autoimmune disease treatments
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Sales and Commercialization: InventisBio generates revenue through the sale of approved drugs. The company has two approved drugs: Anfangning (Garsorasib/D-1553, KRAS G12C inhibitor for NSCLC) was approved by NMPA in November 2024 and shipped nationally in December 2024. Revenue is also generated through licensing and milestone payments from commercial partners. Garsorasib is commercialized in mainland China by Chia Tai Tianqing (正大天晴) under an exclusive license agreement, with InventisBio receiving milestone and potential royalty payments.
2. Licensing and Milestone Payments: InventisBio earns revenue through upfront payments, development milestones, regulatory milestones, and sales royalties from licensing agreements. The D-0316 (EGFR T790M inhibitor) deal with Betta Pharmaceuticals generated 230 million RMB in upfront and development milestones plus sales milestones and royalties. The Garsorasib deal with Chia Tai Tianqing includes development, registration, and commercialization milestones plus sales royalties.
3. Collaborative Development Revenue: The company participates in co-development arrangements where partners fund clinical development costs in exchange for regional commercialization rights, generating non-dilutive capital to support ongoing R&D programs across the pipeline.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

InventisBio discovers, develops, and commercializes innovative small-molecule drugs for oncology, autoimmune diseases, and metabolic disorders. The company has two approved drugs on the market — Garsorasib (D-1553, brand Anfangning), an oral KRAS G12C inhibitor approved by NMPA in November 2024 for KRAS G12C-mutant NSCLC, and D-0316 (licensed to Betta Pharmaceuticals) — alongside three candidates in clinical trials (D-2570 and D-0502 in Phase III registration trials; D-0120 with Phase IIb completed) and preclinical programs targeting WRN, KIF18A, and STAT6.

Product overview

InventisBio is a clinical-stage biotech company with two approved drugs. The company's clinical-stage pipeline centers on four key products: TYK2 inhibitor D-2570 (Nomelcitinib) and oral SERD Taragarestrant (D-0502) are both advancing through Phase III registration trials; URAT1 inhibitor Darbinurad (D-0120) has completed Phase IIb; and KRAS G12C inhibitor Garsorasib/Anfangning (D-1553) received NMPA approval in November 2024 for NSCLC and is being developed for additional indications. The preclinical pipeline includes WRN inhibitor YF087, KIF18A inhibitor YF550, and oral STAT6 degrader YF057. The company maintains partnerships with Chia Tai Tianqing (CTTQ) for Garsorasib commercialization in mainland China and Beta Pharma for EGFR-T790M inhibitor BPI-D0316.

Differentiator

Problem solved

Functional benefit

Brands

• 安方宁 (Anfangning): Brand name for Garsorasib (格索雷塞, D-1553), a KRAS G12C inhibitor approved by NMPA in November 2024 for treatment of KRAS G12C-mutant NSCLC.

Products and services

• Garsorasib (D-1553, 安方宁/Anfangning) Novel oral KRAS G12C inhibitor approved by China's NMPA in November 2024 for KRAS G12C-mutant non-small cell lung cancer (NSCLC), with additional indications in development for colorectal cancer (in combination with cetuximab) and pancreatic cancer. Bicyclic cyclopropyl-substituted piperazine scaffold provides high selectivity and irreversible binding at the SWITCH II pocket. Commercialized in mainland China via exclusive license with Chia Tai Tianqing Pharmaceutical Group (正大天晴药业集团).
• Taragarestrant (D-0502) Oral selective estrogen receptor degrader (SERD) in Phase III registration trials for ER-positive, HER2-negative breast cancer, including patients with ESR1 mutations and those progressing after CDK4/6 inhibitor and endocrine therapy. Offers an oral outpatient alternative to injectable fulvestrant with high bioavailability and favorable pharmacokinetics.
• Nomelcitinib (D-2570) Selective oral TYK2 inhibitor targeting the JH2 pseudokinase domain with approximately 1000-fold selectivity over JAK1, suggesting a wider safety window than broad-spectrum JAK inhibitors. In Phase III registration trials for moderate-to-severe plaque psoriasis and Phase II for active ulcerative colitis. Phase II psoriasis data showed PASI 75 response of 85-90% vs 12.5% placebo at Week 12 with PASI 100 reaching 50% at high dose.
• Darbinurad (D-0120) URAT1 inhibitor for the treatment of hyperuricemia and chronic gout in patients who are unresponsive to standard urate-lowering therapies such as xanthine oxidase inhibitors. Completed Phase IIb clinical trial.
• D-0316 (BPI-D0316) Third-generation EGFR-T790M tyrosine kinase inhibitor for EGFR-mutant non-small cell lung cancer, advanced to Phase II registration trials under license partner Betta Pharmaceuticals (贝达药业). Generates revenue for InventisBio via upfront, milestone, and royalty payments.
• YF087 (WRN helicase inhibitor) Highly selective WRN (Werner syndrome helicase) inhibitor targeting synthetic lethal dependency in MSI-H tumors including endometrial, gastric, colorectal, and ovarian cancers. Currently in preclinical development.
• YF550 (KIF18A inhibitor) KIF18A (kinesin-18 family) small-molecule inhibitor targeting chromosomal instability (CIN) and aneuploidy tumors critical for tumor cell division. Being developed for solid tumors including ovarian, triple-negative breast, colorectal, and lung cancers. Currently in preclinical development.
• YF057 (oral STAT6 degrader) Oral STAT6 protein degrader targeting the STAT6 signaling pathway for autoimmune and inflammatory diseases. Currently in preclinical development.

Quantifiable outcome

• Garsorasib achieved ORR of 52% and DCR of 88.6% in 123 KRAS G12C-mutant NSCLC patients; median PFS 9.1 months, median OS 14.1 months (Phase II, May 2024 data)
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Alphamab Oncology (康宁杰瑞生物制药)coreStrategic or Co-development Partner · 22 December 2025Combination therapy collaboration for D-0502 (oral SERD) with JSKN016 (Alphamab's TROP2/HER3 bispecific ADC). NMPA IND approved December 2025 for treatment of locally advanced or metastatic HR+/HER2- breast cancer. First clinical exploration of oral SERD + ADC combination therapy.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (正大天晴药业集团股份有限公司)coreChannel Partner/ Reseller/ Distributor · 1 August 2023InventisBio entered into an exclusive License and Collaboration Agreement with Chia Tai Tianqing (CTTQ Pharma) in August 2023 for Garsorasib (D-1553/Anfangning). InventisBio granted CTTQ exclusive rights for development, registration, production, and commercialization of Garsorasib in mainland China. InventisBio retained rights outside China. The drug was approved by NMPA on November 8, 2024 and CTTQ handled first nationwide shipment in December 2024.
• Inxite Medical (应世生物科技（南京）有限公司)coreStrategic or Co-development Partner · 7 September 2021Global strategic collaboration for combination therapy development. InventisBio's KRAS G12C inhibitor D-1553 (Garsorasib) combined with Inxite Medical's FAK inhibitor IN10018 for oncology indications. Preclinical studies showed tumor cells develop resistance to KRAS G12C inhibitors via FAK activation, and the combination demonstrated synergistic anti-tumor effects in lung and colorectal cancer models.
• Betta Pharmaceuticals Co., Ltd. (贝达药业股份有限公司)coreTechnology or Integration · 28 December 2018InventisBio transferred China rights (mainland China, Hong Kong, Taiwan) for D-0316 (BPI-D0316, third-generation EGFR-T790M tyrosine kinase inhibitor) to Betta Pharmaceuticals. Betta holds exclusive rights for development and commercialization in the licensed region. InventisBio received upfront and milestone payments totaling 230 million RMB plus sales milestones and royalties. D-0316 advanced to Phase II registration trials for EGFR-mutant NSCLC.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mirati Therapeutics: Developer of Krazati (adagrasib), a competing KRAS G12C inhibitor approved for NSCLC. Acquired by Bristol-Myers Squibb in 2024 for $4.8B. Most direct peer in terms of targeting the same KRAS G12C mutation with similar patient populations and clinical positioning.
• Revolution Medicines: Clinical-stage oncology company developing RAS(ON) inhibitors including RMC-6236 (pan-RAS) and RMC-6291 (KRAS G12C). Directly competes with InventisBio's Garsorasib in KRAS G12C space and represents next-generation approach that could obsolete selective inhibitors.
• Hutchmed (China) Limited: Hong Kong-listed Chinese clinical-stage biotech with multiple approved oncology drugs (surufatinib, fruquintinib, savolitinib) and similar structure-based drug discovery approach. Comparable in scale, business model, and focus on targeted oncology therapies for both China and global markets.
• CStone Pharmaceuticals: Shanghai-based clinical-stage biotech with approved precision oncology drugs (sugemalimab, avapritinib in China). Similar business model of discovering/licensing targeted oncology therapies for China market with focus on KRAS and other difficult targets.

Broad incumbents

• Innovent Biologics: Leading Chinese biotech with multiple approved biologic drugs (sintilimab, etc.) and strong partnership with Eli Lilly. While focused on biologics rather than small molecules, comparable as a major Chinese innovative drug developer with both domestic and international operations.
• BeiGene: Largest Chinese oncology biotech by market cap with approved Brukinsa (zanubrutinib). Significantly larger and more diversified across hematology and solid tumors, but shares the China-origin innovative drug developer profile with global commercialization ambitions.
• Junshi Biosciences: Shanghai-based Chinese biotech with approved PD-1 inhibitor (toripalimab) and broad oncology pipeline. Similar profile to InventisBio as a Shanghai-headquartered Chinese clinical-stage company with STAR Market or HKEX listing and multiple pipeline assets.

Emerging players

• BridgeBio Pharma: US clinical-stage biotech focused on genetic disease and targeted oncology with similar pipeline approach of advancing internally discovered small molecules. Comparable in company stage and R&D focus, though with different therapeutic area mix.
• Arrivent Biopharma: Emerging clinical-stage company developing firmonertinib (EGFR exon 20) and other targeted oncology therapies. Smaller and earlier-stage than InventisBio but focused on similar targeted oncology space with China-origin assets and US operations.

Regional players

• Betta Pharmaceuticals: Chinese specialty oncology company that holds China rights to InventisBio's D-0316 (EGFR-T790M inhibitor) under a 230M RMB licensing deal. A direct commercial partner and peer in the China targeted oncology space, with overlapping product portfolios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InventisBio